Tuberculosis: New active substance BTZ-043 is being tested on patients for the first time
A crucial step in the development of a promising new drug in preclinical tests
Jena/Cape Town. A new antibiotic is currently being clinically tested within a development partnership between the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute - (Leibniz-HKI) and the Tropical Institute at the Ludwig-Maximilian-University Hospital (LMU) in Munich. Since mid-November, the first tuberculosis patients in Cape Town, South Africa, have been treated with the new drug substance BTZ-043 for the first time. The study is carried out within the PanACEA consortium in cooperation with the TASK Applied Science Clinical Research Centre, the University of Cape Town Lung Institute (UCTLI), and the Radboud University Medical Center.